Methionine
CAS 63-68-3
Methionine (CAS 63-68-3) is a Phase 3 pharmaceutical compound with 1 bioactivity target and 104 adverse event associations.
Compound Identity
Matched identifiers and naming fields for the pharmaceutical compound record.
Clinical Development Phase
Highest clinical development phase rendered from the matched compound identifier rows.
Cross-Reference to Cosmetics
Same-CAS ingredient record found in the cosmetics vertical.
Bioactivity & Target Interactions
Target-level activity records with assay counts, activity type, and measured value where present.
| Target | Activity | Value | Assays | Organism |
|---|---|---|---|---|
| - | AC50 | 30000 nM | 28 | - |
| - | IC50 | 60000 nM | 1 | - |
| - | Ki | 61000 nM | 1 | - |
| S-ribosylhomocysteine lyase Unclassified |
Ki | 4.21 | - | Bacillus subtilis (strain 168) |
Adverse Event Associations
DrugCentral / FAERS disproportionality signal rows matched to this compound.
| Reaction PT | Drug AE | LLR | MedDRA |
|---|---|---|---|
| Foetal growth restriction | 15 | 53.771 | 10070531 |
| Device related sepsis | 11 | 44.044 | 10069802 |
| Electrolyte imbalance | 15 | 41.94 | 10014418 |
| Infantile apnoea | 8 | 38.468 | 10077321 |
| Paraplegia | 9 | 36.119 | 10033892 |
| Gaze palsy | 8 | 35.665 | 10056696 |
| Quadriplegia | 8 | 34.669 | 10037714 |
| Selective eating disorder | 8 | 33.818 | 10078069 |
| Faecaloma | 10 | 33.179 | 10056325 |
| Paresis | 8 | 32.882 | 10033985 |
| General physical health deterioration | 26 | 30.924 | 10049438 |
Association rows are source-linked signal records, not incidence rates or clinical causality claims.
Drug Names / RxNorm
Normalized drug-name vocabulary rows, RxCUIs, and source abbreviations.
| Name | RxCUI | Type | Source |
|---|---|---|---|
| Methionine | 6837 | SU | MTHSPL |
| METHIONINE | 6837 | SU | MTHSPL |
| methionine | 6837 | SU | MTHSPL |
| methionine | 6837 | IN | RXNORM |
| L-methionine | 6837 | SY | RXNORM |
Frequently Asked Questions
Short answers generated only from the same visible source-linked rows on this page.
What is Methionine used for in pharmaceutical contexts?
Methionine (CAS 63-68-3) is rendered as a pharmaceutical compound from the matched source rows; no DailyMed product-name rows are present in this page query.
What are the known adverse events for Methionine?
Methionine has 104 DrugCentral/FAERS adverse event associations. Rendered reaction terms include Foetal growth restriction, Device related sepsis, Electrolyte imbalance, Infantile apnoea, Paraplegia. Signal rows are source-linked records and should not be read as incidence rates or causality conclusions.
Is Methionine also used in cosmetics?
Yes. The ingredients table has a same-CAS cosmetic profile for L-Methionine with EU status "permitted".
What clinical phase is Methionine in?
Methionine is rendered with ChEMBL max phase 3.
What bioactivity targets are documented for Methionine?
Methionine has 4 bioactivity rows in this page query. Rendered target entries include S-ribosylhomocysteine lyase.